Synthesis and Assessment of Globotriose–Chitosan Conjugate, a Novel Inhibitor of Shiga Toxins Produced by <i>Escherichia coli</i>

Li, Xuebing; Wu, Peixing; Cheng, Shan; Lv, Xudong

doi:10.1021/jm201570s

Cited by 28 publications

(15 citation statements)

References 64 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These cell-permeative peptides were also protective in a baboon model following Stx2 injection, as renal injury was abated (386). Cytotoxicity of both Stx1 and Stx2 could be neutralized with globotriose conjugated to the polysaccharide chitosan, by binding the toxin (387). This globotriose conjugate was also able to protect mice against STEC O157:H7 challenge.…”

Section: Clinical Considerationsmentioning

confidence: 96%

Recent Advances in Understanding Enteric Pathogenic Escherichia coli

et al. 2013

View full text Add to dashboard Cite

SUMMARY Although Escherichia coli can be an innocuous resident of the gastrointestinal tract, it also has the pathogenic capacity to cause significant diarrheal and extraintestinal diseases. Pathogenic variants of E. coli (pathovars or pathotypes) cause much morbidity and mortality worldwide. Consequently, pathogenic E. coli is widely studied in humans, animals, food, and the environment. While there are many common features that these pathotypes employ to colonize the intestinal mucosa and cause disease, the course, onset, and complications vary significantly. Outbreaks are common in developed and developing countries, and they sometimes have fatal consequences. Many of these pathotypes are a major public health concern as they have low infectious doses and are transmitted through ubiquitous mediums, including food and water. The seriousness of pathogenic E. coli is exemplified by dedicated national and international surveillance programs that monitor and track outbreaks; unfortunately, this surveillance is often lacking in developing countries. While not all pathotypes carry the same public health profile, they all carry an enormous potential to cause disease and continue to present challenges to human health. This comprehensive review highlights recent advances in our understanding of the intestinal pathotypes of E. coli .

show abstract

Section: Clinical Considerationsmentioning

confidence: 96%

Recent Advances in Understanding Enteric Pathogenic Escherichia coli

et al. 2013

View full text Add to dashboard Cite

show abstract

“…49 Table 2 shows some of the examples of chitosan conjugates. Chitosan-doxorubicin Conjugate prepared via succinate linker.…”

Section: Chitosan Based Conjugatesmentioning

confidence: 99%

Polysaccharide-Based Conjugates for Biomedical Applications

et al. 2015

View full text Add to dashboard Cite

Polysaccharides contain different functional groups (such as hydroxyl, amino, carboxylic acid, aldehydes) that make them ideal for conjugation. They are biodegradable, biocompatible, and hydrophilic. Polysaccharide conjugates have been used in drug, gene, and macromolecule delivery, tissue engineering, and other biomedical applications. Polysaccharide conjugates have also been used primarily for solubilization and controlled release of hydrophobic moieties. The advent of nanotechnology, gene therapy, and tissue engineering influenced the way these conjugates are now used. Modern day conjugates are modulated to be thermoresponsive, pH-responsive, photoresponsive, or target-specific (receptor mediated targeting). This Review briefly introduces different polysaccharides followed by different synthetic strategies used for conjugation; finally, recent applications were compiled.

show abstract

“…The strong neutralization effect observed with SUPER TWIG and the Gb3 polymers is due to the fact that the B pentamer of the Stxs contains multiple Gb3-binding sites, so receptor mimics that display multiple copies of the Gb3 trisaccharide bind the toxin tightly. A similar approach as described above was used by another group to display the receptor sugar moiety on chitosan, and they similarly found that the analog neutralizes in vitro and in vivo (48).…”

Section: Receptor Analogsmentioning

confidence: 88%

New Therapeutic Developments against Shiga Toxin-Producing Escherichia coli

Melton‐Celsa

O'Brien

2014

Microbiol Spectr

View full text Add to dashboard Cite

Shiga toxin (Stx)-producing Escherichia coli (STEC) is an etiologic agent of bloody diarrhea. A serious sequela of disease, the hemolytic uremic syndrome (HUS) may arise in up to 25% of patients. The development of HUS after STEC infection is linked to the presence of Stx. STEC strains may produce one or more Stxs, and the Stxs come in two major immunological groups, Stx1 and Stx2. A multitude of possible therapeutics designed to inhibit the actions of the Stxs have been developed over the past 30 years. Such therapeutics are important because antibiotic treatment of STEC infections is contraindicated due to an increased potential for development of HUS. The reason for the increased risk of HUS after antibiotic treatment is likely because certain antibiotics induce expression of the Stxs, which are generally associated with lysogenic bacteriophages. There are a few potential therapeutics that either try to kill STEC without inducing Stx expression or target gene expression within STEC. However, the vast majority of the treatments under development are designed to limit Stx receptor generation or to prevent toxin binding, trafficking, processing, or activity within the cell. The potential therapies described in this review include some that have only been tested in vitro and several that demonstrate efficacy in animals. The therapeutics that are currently the furthest along in development (completed phase I and II trials) are monoclonal antibodies directed against Stx1 and Stx2.

show abstract

Synthesis and Assessment of Globotriose–Chitosan Conjugate, a Novel Inhibitor of Shiga Toxins Produced by Escherichia coli

Cited by 28 publications

References 64 publications

Recent Advances in Understanding Enteric Pathogenic Escherichia coli

Recent Advances in Understanding Enteric Pathogenic Escherichia coli

Polysaccharide-Based Conjugates for Biomedical Applications

New Therapeutic Developments against Shiga Toxin-Producing Escherichia coli

Contact Info

Product

Resources

About